Study wrapper · #403
Current Concepts in Perioperative Guidance and Outcomes in Hand Surgery Patients Taking Glucagon-Like Peptide-1 Receptor Agonists.
Editor's note
This is a narrative concepts review for hand surgeons on managing patients taking GLP-1 receptor agonists, naming semaglutide and tirzepatide specifically. The clinical hinge is delayed gastric emptying and the theoretical aspiration risk around anesthesia, which has driven evolving perioperative guidance. The authors report that the existing hand and orthopedic literature is limited, but that multiple studies to date describe no notable increase in postoperative complications, and they raise open questions about bone and wound healing during rapid weight loss and anesthesia-related risk. As a narrative review it pools no data and grades no evidence; its value is orientation and unresolved-question framing rather than a quantified risk estimate. Useful context on how these peptides intersect with surgical care, appropriately hedged.
Plain-language abstract
GLP-1 medicines such as semaglutide and tirzepatide, used for diabetes and weight loss, are increasingly common among people who need hand surgery. Because these drugs slow how quickly the stomach empties, there has been concern about food remaining in the stomach during anesthesia and being breathed into the lungs, which has changed some surgical guidelines. This review pulls together current thinking for hand surgeons. The authors note the evidence in hand and orthopedic surgery is still limited, but that several studies so far have not found a clear rise in complications after surgery. They also flag possible benefits from better metabolic health, and unanswered questions about how rapid weight loss might affect bone and wound healing and anesthesia safety. This is a summary of expert concepts rather than a study with new data, and it stresses individualized decisions and careful planning.